|
Variable
| |
TAE (n=5) (%)
|
non-TAE (n=46) (%)
|
p value
|
|---|
|
Patient factors
|
|
Age
| |
65 [63–78]
|
71 [16–85]
|
0.526
|
|
Sex
|
Male
|
5 (100.0)
|
37 (80.4)
|
0.571
|
|
Etiology
|
NBNC
|
3 (60.0)
|
22 (47.8)
|
0.999
|
|
ICG-R15 (%)
| |
15.4 [7.5–24.8]
|
13.2 [2.7–75.6]
|
0.727
|
|
Child-Pugh
|
B
|
0 (0.0)
|
2 (4.5)
|
0.999
|
|
Tumor factors
|
|
AFP (ng/ml)
| |
7.2 [2.2–79.6]
|
14.8 [0.8–128900]
|
0.265
|
|
AFP-L3 (%)
| |
0.0 [0.0–11.4]
|
9.9 [0.0–84.0]
|
0.150
|
|
PIVKA-II (mAU/ml)
| |
125.0 [14.0–68901.0]
|
1056.0 [12.0–96988.0]
|
0.974
|
|
Tumor size (mm)
| |
100 [55–130]
|
65 [50–140]
|
0.050
|
|
Tumor number
|
Multiple
|
3 (60.0)
|
12 (26.1)
|
0.144
|
|
Tumor location
|
Right lobe
|
5 (100.0)
|
26 (56.5)
|
0.143
|
|
Perioperative factors
|
|
PVE
|
Present
|
2 (40.0)
|
7 (15.2)
|
0.209
|
|
IBL (mL)
| |
2017 [828–2087]
|
717 [122–3330]
|
0.011
|
|
Operation time (min)
| |
690 [629–791]
|
453 [257–694]
|
0.001
|
|
Blood transfusion
|
Present
|
4 (80.0)
|
9 (19.6)
|
0.012
|
|
Residual tumor
|
R1/2
|
0 (0.0)
|
5 (10.9)
|
0.999
|
|
Postoperative complications
|
CD ≥2
|
3 (60.0)
|
13 (28.3)
|
0.309
|
- Consequent values are expressed as median and range
- TAE trans-arterial embolization, NBNC non-B non-C hepatitis, ICG-R15 indocyanine green retention15, AFP alpha-fetoprotein, AFP-L3 L3 fraction of alfa-fetoprotein, PIVKA-II protein-induced vitamin K absence or antagonist-II, PVE portal vein embolization, IBL intraoperative blood loss CD Clavien-Dindo classification
